قصور الدريقات

إعداد فريق مايو كلينك
26 سبتمبر 2026
  1. Hypoparathyroidism. Eunice Kennedy Shriver National Institute of Child Health and Human Development. http://www.nichd.nih.gov/health/topics/hypopara/Pages/default.aspx. Accessed Oct. 10, 2023.
  2. Goltzman D. Hypoparathyroidism. https://www.uptodate.com/contents/search. Accessed Oct. 10, 2023.
  3. Hypoparathyroidism. The Hormone Health Network. https://www.hormone.org/diseases-and-conditions/hypoparathyroidism. Accessed Oct. 10, 2023.
  4. Preoperative vitamin D level is significantly associated with hypocalcemia after total thyroidectomy. BMC Musculoskeletal Disorders. 2022; doi:10.1186/s12891-022-05977-4.
  5. Hypoparathyroidism. Merck Manual Professional Version. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/parathyroid-disorders/hypoparathyroidism. Accessed Oct. 10, 2023.
  6. Ferri FF. Hypoparathyroidism. In: Ferri's Clinical Advisor 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Oct. 10, 2023.
  7. Orloff LA, et al. American Thyroid Association statement on postoperative hypoparathyroidism: Diagnosis, prevention and management in adults. Thyroid. 2018; doi:10.1089/thy.2017.0309.
  8. Parathyroid changes after RAI in patients with differentiated thyroid carcinoma calcium. Frontiers in Endocrinology. 2021; doi:10.3389/fendo.2021.671787.
  9. Office of Dietary Supplements. https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/. Accessed Oct. 10, 2023.
  10. Phosphorus. Office of Dietary Supplements. https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/. Accessed Oct. 10, 2023.
  11. Medical review (expert opinion). Mayo Clinic. Oct. 18, 2023.
  12. Natpara (prescribing information). Takeda Pharmaceuticals; 2023. https://www.natpara.com/hcp. Accessed Oct. 10, 2023.
  13. Takeda to discontinue manufacturing of NATPAR / NATPARA for patients with hypoparathyroidism at the end of 2024. Takeda. https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara. Accessed Oct. 18, 2023.
  14. Khan AA, et al. Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway Trial. Journal of Bone and Mineral Research. 2022; doi:10.1002/jbmr.4726.